Research
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
Licensing
Biotech stock Argenx (ARGX) broke out of a cup-with-handle base and recently hit an all-time high. For that and other reasons, the maker of a drug to treat the autoimmune disease myasthenia gravis is Monday's pick for IBD 50 Growth Stocks To Watch. The Netherlands-based company turned profitable in 2024. Earnings grew 53% in 2025, and analysts expect profit to rise…
